Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Minson

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Leukemia & Lymphoma|February 29, 2024
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvementAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|July 15, 2021
Glofitamab CD20-TCB bispecific antibodyAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|August 3, 2025
KR-acking the code in non-GCB DLBCL?Adrian Minson, Jeremy Abramson
Leukemia & Lymphoma|June 10, 2023
CAR T-cells in MCL: mind the gapAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|June 9, 2021
Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphomaAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|December 17, 2021
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapseAdrian Minson, Michael Hofman, Michael Dickinson
Clinical & Translational Immunology|August 2, 2021
Dilemmas in the diagnosis and pathogenesis of atypical late-onset familial haemophagocytic lymphohistiocytosisAdrian Minson, Ilia Voskoboinik, Andrew Grigg
British Journal of Haematology|March 14, 2018
Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHDAdrian Minson, Genevieve Douglas, Ian Bilmon, et al.
British Journal of Haematology|May 9, 2024
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are highSamuel Grigg, Adrian Minson, Elizabeth Prins, et al.
Cancers|March 10, 2022
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin LymphomasAdrian Minson, Constantine Tam, Michael Dickinson, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Leukemia & Lymphoma|February 29, 2024
Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvementAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|July 15, 2021
Glofitamab CD20-TCB bispecific antibodyAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|August 3, 2025
KR-acking the code in non-GCB DLBCL?Adrian Minson, Jeremy Abramson
Leukemia & Lymphoma|June 10, 2023
CAR T-cells in MCL: mind the gapAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|June 9, 2021
Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphomaAdrian Minson, Michael Dickinson
Leukemia & Lymphoma|December 17, 2021
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapseAdrian Minson, Michael Hofman, Michael Dickinson
Clinical & Translational Immunology|August 2, 2021
Dilemmas in the diagnosis and pathogenesis of atypical late-onset familial haemophagocytic lymphohistiocytosisAdrian Minson, Ilia Voskoboinik, Andrew Grigg
British Journal of Haematology|March 14, 2018
Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHDAdrian Minson, Genevieve Douglas, Ian Bilmon, et al.
British Journal of Haematology|May 9, 2024
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are highSamuel Grigg, Adrian Minson, Elizabeth Prins, et al.
Cancers|March 10, 2022
Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin LymphomasAdrian Minson, Constantine Tam, Michael Dickinson, et al.
Pageof 3